TITLE

Taking the Trial Out of Clinical Outsourcing

AUTHOR(S)
Hoffman, Joel
PUB. DATE
April 2004
SOURCE
Bio-IT World;Apr2004, Vol. 3 Issue 4, p66
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Discusses the elimination of clinical trials in clinical outsourcing. Cost of clinical trials for drug development; Key to managing relationship with selected outsourcing partners; Importance of communication to the success of projects; Factors that influence building and maintenance of the relationship with outsourcing partners.
ACCESSION #
14173967

 

Related Articles

  • Precautionary Principles. Corneliussen, Filippa // European Pharmaceutical Executive;May/Jun2006, p58 

    The article focuses on need for the biopharmaceutical industry to examine the oversight framework to regulate biomedical research and development activities in the private sector and to address how these laws and regulations affecting individual companies differ depending on the specific...

  • Phase 0 clinical trial - an overview. Satija, Aanchal // International Journal of Students' Research;Sep2011, Vol. 1 Issue 3, p76 

    Drug discovery begins in the laboratory with target identification and validation followed by pre-clinical and clinical development. The entire process takes around 10 to 15 years. It is associated with high costs and a high rate of failure. The probability of a drug going beyond Phase I testing...

  • Leaving the bench for the clinic. Frantz, Simon // Nature Reviews Drug Discovery;Apr2004, Vol. 3 Issue 4, p371 

    The increased demands on Clinical Research Associates mean that inexperienced applicants from academia should learn more about the clinical development process.

  • Data Monitoring Committees in Practice. Kerr, David; McBride, Ruth; Shemanski, Lynn // Applied Clinical Trials;Mar2004, Vol. 13 Issue 3, p42 

    Provides information about data monitoring committees DMC) and clinical trials in the U.S. Role of DMC; Reference to the draft guidance published by the Food and Drug Administration for deciding the need of the DMC in clinical trials; Scenarios under which a DMC might recommend stopping a...

  • Clinical drug trials and the role of the nurse. Rath, Louise; Hitchcock, Alison; Oakley, Marion; Graham, Janet // Australian Nursing Journal;May2003, Vol. 10 Issue 10, p1CU 

    Presents an overview of how clinical drug trials are conducted in Australia. Phases of drug trials; Ethical considerations; Role of the research and clinical nurse in the trials. INSET: Common words associated with clinical drug trials.

  • News Update.  // Applied Clinical Trials;Jun2000, Vol. 9 Issue 6, p12 

    Reports on developments relating to clinical trial management as of June 2000. Inclusion of the United States Food and Drug Administration's approval of Novartis Pharmaceuticals Corp.'s Exelon, capsules for treating Alzheimer's disease; Phase 3 study of Sensus Drug Development Corp.'s use of...

  • Trials shock fuels public interest.  // European Pharmaceutical Executive;May/Jun2006, p16 

    The article reports on how the Parexel clinical trial elicited a surge of interested volunteers from the general public. Enter Trials is a web site through which patients can register to participate in clinical trials. It reported that after the Parexel incident, its server hits rose from...

  • Novartis to begin ADHD study in girls.  // PharmaWatch: CNS;October 2003, Vol. 2 Issue 10, p12 

    Reports on the commencement of a new clinical study to evaluate the efficacy and safety of Ritalin LA extended release capsules in girls aged 12 to 17 years old with attention-deficit/hyperactivity disorder (ADHD). Study design; Objective of the study; Potential impact of the study in the...

  • Transition Therapeutics: showing potential in hepatitis.  // PharmaWatch: Monthly Review;Sep2006, Vol. 5 Issue 9, p33 

    The article reports that Toronto-based Transition Therapeutics Inc. has posted positive 12-week data from a phase I/II trial investigating the safety and efficacy of HCV-IET in hepatitis C non-responders. HCV-IET combines Transition's interferon enhancer EMZ702 with the current standard of care...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics